Compliance and outcome in patients treated with antipsychotics: The impact of extrapyramidal syndromes

CNS Drugs

Volumn 5, Issue SUPPL. 1, 1996, Pages 13-20

  Hummer, Martina ^a   Wolfgang Fleischhacker, W ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

EXTRAPYRAMIDAL SYNDROME; HUMAN; MEDICAL LITERATURE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 9544248641     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199600051-00004     Document Type: Review

References (53)

1. Davis JM. Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ, editors. Comprehensive textbook of psychiatry. 3rd ed. Baltimore: Williams and Wilkins, 1980
2. Kane JM. Treatment of schizophrenia. Schizophrenia Bull 1987; 13 (1): 133-56
3. Maurer K, Biehl H. Klinikaufenthalte und produktive Rückfälle bei ersterkrankten Schizophrenen. Determinanten des Zeitverlaufs zwischen stationären Aufnahmen bzw. schizophrenen Rezidiven über fünf Jahre. Nervenheilkunde 1988; 7: 279-90
4. Kane JM. Compliance issues in outpatient treatment. J Clin Psychopharmacol 1985; 5 Suppl. 3: 22S-7
5. Kissling W. Consensus regarding indication for prophylactic neuroleptic treatment - necessary, but unattainable? In: Barnes TRE, editor. Depot neuroleptics - a consensus. London: Mediscript, 1988: 41-6
6. Gaebel W, Pietzcker A. Indikation zur neuroleptischen Langzeitmedikation - Standardverfahren oder individual-prognostisch geleite Intervention? Nervenarzt 1983; 54: 467-76
7. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14: 105-22
8. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214-7
9. Pfeiffer W, Kockott G, Fischl B, et al. Unerwünschte Wirkungen psychopharmakologischer Langzeittherapie auf die sexuellen Funktionen. Psychiatr Prax 1991; 18: 92-8
10. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992; 22: 787-97
11. Haase HJ. Das therapeutische Achsensyndrom neuroleptischer Medikamente und seine Beziehungen zu extrapyramidaler Symptomatik. Fortschr Neurol Psychiatr 1967; 29: 245
12. Stille G, Hippius H. Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmakopsychiat 1971; 4: 182-91
13. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990; 47: 761-8
14. McEvoy JP, Schooler NR, Wilson WH. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol Bull 1991; 27: 97-101
15. Cohen BM, Keck PE, Satlin A, et al. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991; 29: 1215-9
16. Chakos MH, Mayerhoff DI, Loehel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992; 28: 81-6
17. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67-72
18. Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41: 1036-9
19. Van Putten T, May PRA, Marder SR. Response to antipsychotic medication: the doctors and the consumers view. Am J Psychiatry 1984; 141: 16-9
20. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992; 22: 787-97
21. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347-52
22. Hogan TD, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177-83
23. Marder SR, Van Putten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1985; 41: 1025-9
24. Weiden PJ, Dixon L, Frances A, et al. Neuroleptic noncompliance in schizophrenia. In: Tamminga CA, Schulz SC, editors. Schizophrenia research. Advances in Neuropsychiatry and Psychopharmacology. New York: Raven Press, 1991; 1: 285-96
25. Schooler N. Predictors of stabilization in schizophrenia. Presented at the 141st American Psychiatric Association Annual Meeting, Montreal, Canada, 1988
26. Fleischhacker WW, Meise U, Günther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl. 1994; 382: 11-5
27. Baldessarini RJ, Fleischhacker WW, Sperk G. Pharmakotherapie in der Psychiatrie. Stuttgart: Thieme Verlag, 1991, pp.186 ff
28. Hollister LE, Chaffey EM, Klett CJ. Abnormal symptoms, signs and laboratory tests during treatment with phenothiazine derivatives. Clin Pharmacol Ther 1960; 1: 284-93
29. Goldman D. Parkinsonism and related phenomena from administration of drugs: their production and control under clinical conditions and possible relation to therapeutic effect. Rev Can Biol 1961; 20: 549-60
30. Bishop MP, Gallant DM, Sykes TF. Extrapyramidal side effects and therapeutic response. Arch Gen Psychiatry 1965; 13: 155-62
31. Lieberman JA, Kane JM, Sarantakos S, et al. Prediction of relapse in schizophrenia. Arch Gen Psychiatry 1987; 44: 597-603
32. Buchanan RW, Kirkpatrick B, Summerfelt A, et al. Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry 1992; 32: 72-8
33. Blackwell B. Treatment adherence. Br J Psychiatry 1976; 129: 513-31
34. Middelboe T. Predictors of treatment compliance in long-term mentally ill. Eur Neuropsychopharmacol 1995; 5 (3): 318
35. Marder SR, Mebane A, Chien C, et al. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983; 140: 470-2
36. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52: 173-88
37. Casey DH. Extrapyramidal syndromes: epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 1996; 5 Suppl. 1: 1-12
38. Fleischhacker WW, Miller CH, Barnas C, et al. The effect of activation procedures on neuroleptic-induced akathisia. Br J Psychiatry 1993; 163: 781-4
39. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994; 51: 963-74
40. Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987; 144: 1148-53
41. Whitworth AB, Fleischhacker WW. Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 1995; 9 Suppl. 5: 21-7
42. Remington G, Bezchlibnyk-Butler K. Management of neuroleptic-induced extrapyramidal symptoms. CNS Drugs 1996; 5 Suppl. 1: 21-35
43. Smith JM. Abuse of antiparkinsonian drugs - a review of the literature. J Clin Psychiatry 1980; 41: 351-4
44. Sofair J, Campion J, Angrist B. High dose trihexyphenidyl abuse with psychological dependence. J Clin Psychopharmacol 1983; 3: 263-4
45. Heischhacker WW, Barnas C, Günther V, et al. Mood-altering effects of biperiden in healthy volunteers. J Affect Disord 1987; 12: 153-7
46. Tandon R, Mann NA, Eisner WH, et al. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1990; 31; 235-41
47. Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A double-blind cross-over study. Br J Psychiatry 1995; 166: 241-3
48. World Health Organisation. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990; 156: 412
49. Keepers G, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psycopharmacol 1987; 7: 342-3
50. Keepers G, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148: 85-9
51. Casey DE. Neuroleptic-induced acute dystonia. In: Lange AE, Weiner WJ, editors. Drug-induced movement disorders. New York: Futura Publishing Co., Inc., 1992: 21-40
52. Choy-Kwong M, Lipton RB. Cocaine withdrawal dystonia. Neurology 1990; 40: 863-4
53. Fleischhacker WW, Roth SD, Kane JM. The pharmacological treatment of neuroleptic induced akathisia. J Clin Psychopharmacol 1990; 10: 12-21